Such a discrepancy may indicate that the proportion of ALK amplification, as an oncogene driver, is higher than that of an EGFR mutation, or that the application of alectinib is more effective than EGFR-TKIs in the treatment of co-mutated lung adenocarcinoma patients. Here, EGFR is linked to lung adenocarcinoma.